Anteris Technologies Global Starts US PARADIGM Trial Enrolment

Why It Matters

Enrollment and reimbursement clearance accelerate DurAVR’s market entry, while fresh capital mitigates financing risk and supports scaling in a competitive TAVR landscape.

Key Takeaways

• US enrollment begins for PARADIGM trial targeting 1,000 patients
• Cash balance rose to $283.2M after $320M capital raise
• Medtronic invested $90M via private placement
• CMS TAVR coverage clears reimbursement hurdle for DurAVR
• ISO 13485 certification achieved for DurAVR manufacturing

Pulse Analysis

The transcatheter aortic valve replacement (TAVR) market has expanded rapidly as clinicians seek less invasive solutions for aortic stenosis. Anteris Technologies Global’s DurAVR system, a next‑generation valve designed for lower-profile delivery, entered the pivotal PARADIGM trial, a randomized study that will compare its performance against established commercial TAVRs in 1,000 patients. By launching U.S. enrollment, Anteris moves the trial into the world’s largest TAVR market, where data can influence payer decisions and shape future device adoption.

Financially, Anteris reinforced its balance sheet with a $320 million capital raise in January 2026, comprising a $230 million public offering and a $90 million private placement led by Medtronic. The infusion lifted cash and restricted cash to $283.2 million, a dramatic increase from $12.6 million at year‑end. This liquidity cushion not only funds the costly trial and manufacturing scale‑up but also signals confidence from a major industry player, potentially easing future financing rounds and positioning Anteris for strategic collaborations.

The U.S. Centers for Medicare & Medicaid Services (CMS) recently issued a national coverage determination for TAVR procedures, effectively clearing the reimbursement pathway for DurAVR patients enrolled in PARADIGM. This regulatory win is expected to accelerate site participation and patient recruitment, while the ISO 13485 certification validates Anteris’s manufacturing quality system. Nonetheless, the company faces ongoing cash burn and the inherent risk that enrollment or trial outcomes fall short of expectations, factors that will heavily influence eventual FDA approval and commercial launch.